

Restructuring the National Cancer Clinical Trials Enterprise

Clinical Trials Working Group
NCAB Implementation Update

James H. Doroshow, MD

February 6, 2007

Common Themes of the Restructuring Plan

- **Enterprise-Wide/Integrated Management**
- **Prioritization/Scientific Quality**
- **Coordination**
- **Standardization**
- **Operational Efficiency**

Enterprise-Wide: Integrated Management

CTWG Recommendation:

- Establish an **external** clinical trials oversight committee to advise NCI Director
- Develop a coordinated organizational structure **within NCI** to manage the clinical trials enterprise

Clinical Trials Advisory Committee (CTAC)

- Federal advisory committee chartered in March 2006
<http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm>
- Membership:
 - ✓ Ten members current Boards (NCAB, BSA, BSC, DCLG)
 - ✓ Fourteen new members from extramural clinical trials community
- First meeting: January 10, 2007
- Functions:
 - ✓ Provide extramural oversight for CTWG implementation initiatives institute-wide, including clinical trial informatics
 - ✓ Strategic advice regarding entire NCI clinical trials portfolio
 - ✓ Advise on use of correlative science and quality of life funds
 - ✓ Develop recommendations for additional refinements to NCI-supported clinical trials system based on ongoing analyses: operational efficiency, financial analysis of phase III trial costs, and central IRB function
 - ✓ Advise on outcome of formal evaluations

Clinical Trials Advisory Committee (CTAC)

- **Informatics working group**
 - Provide interface with NCICB and oversight of CTWG clinical trials IT initiatives
- **Public/Private partnership working group**
 - Initiatives to enhance NCI-sponsored clinical trials through prospective interactions with the private sector
- **Coordination working group**
 - Bring together Cancer Center Directors, Cooperative Group Chairs, and SPORE PIs to harmonize program guidelines and facilitate clinical trials interactions


Clinical Trials Operations Committee (CTOC)

- Internal NCI committee established in December, 2005 to provide strategic oversight for NCI clinical trials programs and infrastructures
- Chair, Dr. John Niederhuber
- Membership from all NCI Divisions, Offices, and Centers involved in NCI-supported clinical trials including DCTD, DCP, OCTR, DCCPS, CCR, DCEG, NCICB, DEA and CCCT

CTOC Activities Update

- Reviewed all RFAs and PAs involving clinical trials in past year
- Provided input to NCICB on the CTWG informatics implementation plan
- Evaluating feasibility of modifying clinical trials data reporting requirements for grant funded trials (e.g. R01, Program Project grants, etc.)
- Approved minority accrual supplements
- Portfolio reviews
 - Programmatic
 - Disease specific

Integrated Management



Common Themes of the Restructuring Plan

- Enterprise-Wide/Integrated Management
- **Prioritization/Scientific Quality:** Involve all stakeholders in design and prioritization of clinical trials that address the most important questions, using the tools of modern cancer biology
- Coordination
- Standardization
- Operational Efficiency

Progress: Prioritization/Scientific Quality

- **IDSC has been established with 5 task forces**
 - ✓ Formally integrated into establishment of CTEP drug development planning
- **Disease-specific Steering Committees**
 - ✓ GI and GYN up and running
 - ✓ H&N operational: Face-to-Face 12/06
 - ✓ Symptom-Management/HRQOL launched: Face-to-Face 5/07
 - ✓ SOPs developed
- **SPORE members, community oncologists and advocates have been elected to all SC's**
- **Task Force defined prioritization criteria for correlative science studies**

Prioritization/Scientific Quality: 2007 Goals

- **Expand role of IDSC for early phase trial prioritization utilizing evolving Task Forces**
 - ✓ Identify priority issues in phase II trial design
 - ✓ Develop standards for biomarkers in early phase clinical trials
 - ✓ Review the clinical development plans for angiogenesis and signal transduction inhibitors
- **Complete implementation of H&N and Symptom Management SC's; SOTS meeting in GI and GYN**
- **Establish process to ensure that correlative science and quality of life studies conducted in association with clinical trials conform to standard protocols and standardized lab practices: Biomarker Standardization Workshop Spring '07**

Common Themes of the Restructuring Plan

- Enterprise-Wide/Integrated Management
- Prioritization/Scientific Quality
- **Coordination:** Coordinate clinical trials research through data sharing and providing incentives for collaboration
- Standardization
- Operational Efficiency

Coordination Initiatives

- Establish a comprehensive database containing regularly-updated information on all NCI-funded clinical trials
- Realign NCI funding, academic recognition, and other incentives to promote collaborative team science and clinical trial cooperation

Promote Collaborative Team Science

- **Award Guideline Modification**
 - Cooperative Group program guidelines are in the process of modification to reflect collaboration with SPOREs and Cancer Centers positively
 - Plan to modify SPORE and Cancer Center program guidelines to consider collaboration with Cooperative Groups positively
- **Funding Practice Modification**
 - Evaluating feasibility of accruing patients to SPORE and Cancer Center clinical trials through NCI's Cancer Trials Support Unit (CTSU)
- **New Forms of Recognition for Cancer Clinical Investigators**
 - Cancer Clinical Investigator Team Leadership Award to recognize mid-level clinical investigators for exceptional participation in NCI-funded collaborative clinical trials

Common Themes of the Restructuring Plan

- Enterprise-Wide/Integrated Management
- Prioritization/Scientific Quality
- Coordination
- **Standardization:** Standardize informatics infrastructure and clinical research tools
- Operational Efficiency

Standardization Initiatives

- 1) Informatics infrastructure interoperable with caBIG™
- 2) Standard Case Report Forms incorporating Common Data Elements
- 3) Credentialing system for investigators and sites that is recognized and accepted by NCI, industry sponsors, clinical investigators and clinical trial sites
- 4) Establish commonly accepted clauses for clinical trial contracts

Progress: Standardization

- **CaBig Clinical Trials Steering Committee created: Clinical trialists, statisticians, IT experts—First meeting March '07**
 - Establish strategic priorities and oversight for all CTWG informatics initiatives
 - Ensure coordination of CTWG informatics activities across NCI-supported clinical trials activities
- **Inventory of NCI electronic CRFs is underway**
- **Preliminary meeting with industry held to discuss standard clauses for clinical trials contracts**

Common Themes of the Restructuring Plan

- Enterprise-Wide/Integrated Management
- Prioritization/Scientific Quality
- Coordination
- Standardization
- **Operational Efficiency:** Use resources most efficiently through improved cost-effectiveness and accrual rates, and more rapid trial initiation

Operational Efficiency Initiatives


- 1) Restructure the funding model for phase III efficacy trials to incentivize more rapid rates of patient accrual
- 2) Identify the institutional barriers that prolong the time from concept approval to accrual of the first patient, and develop solutions for overcoming these barriers
- 3) Expand current outreach programs to increase the recruitment of minority populations to cancer clinical trials
- 4) Develop approaches for enhancing adoption of centralized Institutional Review Board processes

Financial Analysis

A financial analysis of phase III trial costs has been initiated:

- Identify areas of inadequate funding, where increased financial compensation could significantly improve clinical trial conduct
- Identify areas of overlap, duplication or redundancy which, if eliminated, could result in cost-savings
- Identify best practices for budget allocations and financial management that could potentially be standardized across Cooperative Groups
- Assess the cost savings that might result from closing sites that accrue very low numbers of patients

Process Flow Map for Phase III Studies



Dilts, D. M. et al. J Clin Oncol; 24:4553-4557 2006

Enhance Minority Accrual

- Trans-NCI Partnership formed to propose mechanisms and solicit concepts
- Programs receiving FY06 supplemental funding included:
 - Cancer Disparities Research Partnerships to expand available trials beyond radiation oncology to surgical and medical oncology trials
 - MBC COP and Patient Navigator Research Program to evaluate the impact of Patient Navigators on minority accrual in cancer prevention and control trials capitalizing on the experience of both programs
- Timeline calls for expansion in FY07

Enhance Adoption of Central IRB

- A analysis of the barriers to the acceptance of the NCI Central Institutional IRB (CIRB) has been initiated
- An analysis of the potential cost savings that would result from the use of the CIRB has been funded

Evaluation and Outcome Measures

- **Structured evaluation system**
 - Designed by experienced evaluation specialists
 - Blend of quantitative and qualitative measures
 - External clinical trials expert panel has reviewed the proposed measures
- **Baseline evaluation to be performed in FY07**
- **Periodic evaluations to assess impact of restructuring**